Clinical Trials Logo

MRD-positive clinical trials

View clinical trials related to MRD-positive.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03919526 Completed - Clinical trials for Acute Lymphoblastic Leukemia

Anti-CD19/CD22 Bispecific Chimeric Antigen Receptor(CAR)-T Cell Therapy for Measurable Residual Disease(MRD) Positive ALL

Start date: August 11, 2019
Phase: Phase 1
Study type: Interventional

To evaluate the safety and efficacy of CD19/CD22 Bispecific chimeric antigen receptor (CAR)-T for the treatment of measurable residual disaese (MRD)-positive B cell acute lymphoblastic leukemia. Patients will be given a conditioning chemotherapy regimen of fludarabine and cyclophosphamide followed by a single infusion of CD19/CD22 CAR+ T cells.